Shilpa Medicare’s USFDA Inspection Analyzed
Shilpa Medicare recently finished a ten-day inspection by the US Food and Drug Administration (USFDA) at their Jadcherla, Telangana facility. This inspection, completed on November 21, 2025, resulted in the issuance of a Form 483, which is a standard report outlining areas for improvement. Importantly, none of the observations from this inspection were repeated from prior reviews.
Key Points
- USFDA inspected Shilpa Medicare’s Jadcherla facility on Nov 21, 2025.
- Form 483 issued, revealing eight observations, none recurring.
- Facility produces injectables, tablets, and capsules globally.
- US sales are minimal, less than 1% of total revenue.
- Approved by EMA, Canada, Brazil, and Australia regulators.
- Focus on continuous improvement within the manufacturing process.
Facility Overview
The Jadcherla unit is a major part of Shilpa Medicare’s operations. It’s designed to handle the entire process of making medicines, from packaging to storing them until they are shipped out. This includes producing sterile injectables, common oral tablets and capsules.
Global Reach
Shilpa Medicare’s products made at this facility aren’t just for the United States. They’re also sent to Europe, Brazil, Canada, and Australia. This shows the company’s reach and commitment to supplying medications worldwide.
Sales Impact
The sales generated by the Jadcherla facility represent a small part of Shilpa Medicare’s overall business. Specifically, US sales account for less than 1% of the company’s revenue for the first half of their financial year (FY25-26) and less than 5% for the entire previous year (FY24-25).
Regulatory Compliance
This facility holds approvals from key regulatory bodies, including the European Medicines Agency (EMA), Health Canada, Anvisa (Brazil), and the Therapeutic Goods Administration (TGA) in Australia. This signifies a strong commitment to meeting high quality standards.
Meeting regulatory expectations is paramount to sustained global market access for Shilpa Medicare.
